DIABETIC DYSLIPIDEMIA - TREATMENT IMPLICATIONS

被引:0
|
作者
BETTERIDGE, DJ
机构
关键词
CARDIOVASCULAR DISEASE; DIABETES; DIABETES TREATMENT; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is associated with increased morbidity and mortality from cardiovascular disease in the absence of the major risk factors-cigarette smoking, hypertension and serum cholesterol concentration. When these risk factors are present, the attributable risk to each factor alone and to the combination of risk factors is higher in diabetic than in nondiabetic subjects. Thus, stringent measures to correct risk factors for cardiovascular disease have been advocated in diabetic patients. In addition to hypercholesterolaemia, other lipid and lipoprotein abnormalities collectively referred to as diabetic dyslipidaemia probably contribute to vascular risk. Hypertriglyceridaemia, often associated with low high-density-lipoprotein cholesterol, is common in NIDDM patients and is associated with insulin resistance. Recent information in diabetic patients, pointing to the association of hypertriglyceridaemia with accumulation of remnant particles and alterations in low-density-lipoprotein subfractions, helps to explain the strong relationship between hypertriglyceridaemia and vascular risk in these individuals. Although there are as yet no intervention trials with lipid-lowering diets or drugs in diabetic patients to judge the impact on vascular disease, national and international bodies have furnished guidelines for the identification and treatment of lipid disorders in diabetes in the hope of reducing the huge toll of vascular disease in these patients.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 50 条
  • [41] Atherogenic dyslipidemia and diabetic nephropathy
    Giuseppina Russo
    Pamela Piscitelli
    Annalisa Giandalia
    Francesca Viazzi
    Roberto Pontremoli
    Paola Fioretto
    Salvatore De Cosmo
    Journal of Nephrology, 2020, 33 : 1001 - 1008
  • [42] Diabetic dyslipidemia and its therapy
    Garg, A
    Grundy, SM
    DIABETES REVIEWS, 1997, 5 (04): : 425 - 433
  • [43] Diabetic dyslipidemia: evaluation and mechanism
    Yanai, Hidekatsu
    Hirowatari, Yuji
    Yoshida, Hiroshi
    GLOBAL HEALTH & MEDICINE, 2019, 1 (01): : 30 - 35
  • [44] Pharmacological management of diabetic dyslipidemia
    Filippatos, T. D.
    Florentin, M.
    Georgoula, M.
    Elisaf, M. S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (02) : 187 - 200
  • [45] Creation of diabetic dyslipidemia in in mice
    Kako, Y
    Masse, M
    Tall, AR
    Goldberg, IJ
    DIABETES, 2000, 49 : A13 - A13
  • [46] Diabetic dyslipidemia: beyond LDL
    Merkel, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2009, 134 (20) : 1067 - 1073
  • [47] Diabetic dyslipidemia or 'diabetes lipidus'?
    Muacevic-Katanec, Diana
    Reiner, Zeljko
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (03) : 341 - 348
  • [48] MANAGEMENT OF DYSLIPIDEMIA IN DIABETIC NEPHROPATHY
    Mamasakhlisi, A.
    ATHEROSCLEROSIS, 2020, 315 : E264 - E264
  • [49] Atherogenic dyslipidemia and diabetic nephropathy
    Russo, Giuseppina
    Piscitelli, Pamela
    Giandalia, Annalisa
    Viazzi, Francesca
    Pontremoli, Roberto
    Fioretto, Paola
    De Cosmo, Salvatore
    JOURNAL OF NEPHROLOGY, 2020, 33 (05) : 1001 - 1008
  • [50] Role of the Gut in Diabetic Dyslipidemia
    Stahel, Priska
    Xiao, Changting
    Nahmias, Avital
    Lewis, Gary F.
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11